Introduction The progression of amyotrophic lateral sclerosis (ALS) leads to a decline of the nutritional status that represents an independent prognostic factor for survival. Recent studies recognize the muscle tissue as an endocrine organ able to release several molecules, called myokines. Among them, irisin seems to be involved in the regulation of metabolism, body weight and development and function of the nervous system. Objectives (1) To evaluate irisin serum levels in patients with ALS, with comparison to healthy subjects; (2) to assess the possible association of circulating irisin levels of ALS patients with the metabolic status, clinical and biochemical features. Methods We performed an observational, cross-sectional study in 50 ALS patients and 32 age- and sex-comparable healthy controls. Patients underwent to a complete set of neurological, pulmonary and nutritional evaluations. Serum irisin concentration was measured by enzyme immunoassay. According to indirect calorimetry, ALS patients were divided into a normo-metabolic patient group (n=24) and a hyper-metabolic patient group (n=26). Results ALS patients showed significantly higher serum irisin levels compared to healthy subjects (51.0± 37.8 vs 13.1±2.2 ng/mL, p<0.0001). Hyper-metabolic ALS patients displayed higher serum irisin levels compared to normometabolic ALS patients and healthy controls (p<0.0009 and p<0.0001, respectively). Serum irisin levels showed significant association with the ALSFRS-R (β=-1.18, p=0.042), Forced Vital Capacity (β = − 0.64, p=0.013), Fat Mass (β=-1.44, p=0.034), pCO2 arterial blood levels (β=2.67, p=0.003), HCO3 − arterial blood levels (β=5.44, p=0.001) and Free Fat Mass (β=1.07, p=0.025) adjusted for sex, age and metabolic status. Conclusions ALS patients with impaired metabolic status showed higher serum irisin levels compared to normo-metabolic ALS patients and healthy subjects. Irisin levels were also negatively correlated with the extent of functional and respiratory impairment, due to as yet unknown causes, being more elevated in patients with greater disability

Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status / C. Lunetta, A. Lizio, L. Tremolizzo, M. Ruscica, C. Macchi, N. Riva, P. Weydt, E. Corradi, P. Magni, V. Sansone. - In: JOURNAL OF NEUROLOGY. - ISSN 0340-5354. - 265:12(2018 Dec), pp. 3001-3008. [10.1007/s00415-018-9093-3]

Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status

M. Ruscica;C. Macchi;P. Magni
Penultimo
;
V. Sansone
Ultimo
2018

Abstract

Introduction The progression of amyotrophic lateral sclerosis (ALS) leads to a decline of the nutritional status that represents an independent prognostic factor for survival. Recent studies recognize the muscle tissue as an endocrine organ able to release several molecules, called myokines. Among them, irisin seems to be involved in the regulation of metabolism, body weight and development and function of the nervous system. Objectives (1) To evaluate irisin serum levels in patients with ALS, with comparison to healthy subjects; (2) to assess the possible association of circulating irisin levels of ALS patients with the metabolic status, clinical and biochemical features. Methods We performed an observational, cross-sectional study in 50 ALS patients and 32 age- and sex-comparable healthy controls. Patients underwent to a complete set of neurological, pulmonary and nutritional evaluations. Serum irisin concentration was measured by enzyme immunoassay. According to indirect calorimetry, ALS patients were divided into a normo-metabolic patient group (n=24) and a hyper-metabolic patient group (n=26). Results ALS patients showed significantly higher serum irisin levels compared to healthy subjects (51.0± 37.8 vs 13.1±2.2 ng/mL, p<0.0001). Hyper-metabolic ALS patients displayed higher serum irisin levels compared to normometabolic ALS patients and healthy controls (p<0.0009 and p<0.0001, respectively). Serum irisin levels showed significant association with the ALSFRS-R (β=-1.18, p=0.042), Forced Vital Capacity (β = − 0.64, p=0.013), Fat Mass (β=-1.44, p=0.034), pCO2 arterial blood levels (β=2.67, p=0.003), HCO3 − arterial blood levels (β=5.44, p=0.001) and Free Fat Mass (β=1.07, p=0.025) adjusted for sex, age and metabolic status. Conclusions ALS patients with impaired metabolic status showed higher serum irisin levels compared to normo-metabolic ALS patients and healthy subjects. Irisin levels were also negatively correlated with the extent of functional and respiratory impairment, due to as yet unknown causes, being more elevated in patients with greater disability
ALS; Irisin; Metabolism; Myokine; Serum
Settore MED/04 - Patologia Generale
Settore MED/05 - Patologia Clinica
Settore MED/26 - Neurologia
Settore MED/13 - Endocrinologia
Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio
dic-2018
22-ott-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
Lunetta2018_Article_SerumIrisinIsUpregulatedInPati.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 867.05 kB
Formato Adobe PDF
867.05 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/597790
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 19
social impact